European Primary Care Cardiovascular Society

Benefits of rapid uptitration of HF medications independent of baseline renal function

3' education - July 13, 2023 - Jozine ter Maaten, MD, PhD

ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF

3' education - July 13, 2023 - Robert Mentz, MD

Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF

3' education - July 13, 2023 - Jasper Brugts, MD, PhD

Regional differences in prescription of PCSK9i therapy across Europe

10' education - July 12, 2023 - Maciej Banach, MD, PhD

The right therapy for the right patient

3' education - June 26, 2023 - Stephen Nicholls, MD

Elevated inflammation markers in diabetes: a cause or a consequence?

3' education - June 26, 2023 - Peter Libby, MD

How to manage patients with elevated Lp(a)

3' education - June 26, 2023 - Florian Kronenberg, MD, PhD

Relevance of adipose tissue in cardio-metabolic complications

3' education - June 26, 2023 - Antonio Vidal-Puig, MD

Fitting in bempedoic acid in the arsenal of lipid-lowering therapies

3' education - Mar. 30, 2023 - Prof. Kausik Ray, MD

Lowering LDL-c and CV risk with new evidence-based non-statin treatment

3' education - Mar. 18, 2023 - Prof. Peter Libby, MD

No association of early eGFR decline after transitioning to ARNI with adverse outcomes

3' education - Mar. 14, 2023 - Safia Chatur, MD

A phase 3 trial with bempedoic acid: Strengths and limitations

3' education - Mar. 13, 2023 - Prof. Eugene Yang, MD

Low-carbohydrate high-fat diet is associated with CV events

3' education - Mar. 11, 2023 - Liam Brunham, MD, PhD

Bempedoic acid in CV outcomes trial in statin-intolerant patients

3' education - Mar. 10, 2023 - Prof. Steven Nissen, MD

Results for oral PCSK9 inhibitor promising to proceed to phase 3 trials

3' education - Mar. 9, 2023 - Prof. Christie Ballantyne, MD

CODE-EHR, a framework for the use of electronic health record data in clinical research

5' education - Oct. 13, 2022 - Prof. Folkert Asselbergs, MD, PhD

Risk of CVD in patients with autoimmune diseases

5' education - Oct. 12, 2022 - Prof. Naveed Sattar, MD, PhD

DOAC versus VKA in rheumatic atrial fibrillation

3' education - Sep. 15, 2022 - Prof. Ganesan Karthikeyan, MD

What are the real effects of statins on muscle symptoms?

3' education - Sep. 12, 2022 - Prof. Colin Baigent, MD

Aspirin or P2Y12i monotherapy for secondary prevention in patients with CAD?

3' education - Sep. 5, 2022 - Prof. Marco Valgimigli, MD, PhD

No threshold in the association of alcohol consumption with blood pressure in healthy persons

Literature - Sep. 26, 2023 - Di Federico S, et al. - Hypertension. 2023

In a meta-analysis of 7 nonexperimental cohort studies, there was a positive, almost linear association with no evidence of a threshold between alcohol consumption at baseline and systolic blood pressure levels during follow-up in healthy persons.

Global association of the PURE healthy diet score with health outcomes

Literature - Sep. 25, 2023 - Mente A et al. - Eur Heart J. 2023

Using data of persons from 80 countries, it was demonstrated that a diet with higher amounts of fruit, vegetables, legumes, nuts, and a moderate amount of fish and (whole-fat) diary was associated with lower risk of CVD and mortality globally, especially in low-income countries.

Consistent benefit of SGLT2 inhibitors on CV outcomes across various patient populations

Literature - Sep. 21, 2023 - Usman MS, et al. - J Am Coll Cardiol. 2023

What are the effects of SGLT2 inhibitors on CV outcomes across different subgroups of patients? This was investigated in a meta-analysis of 13 RCTs in patients with HF, T2D or CKD, and in patients with varying combinations of these diseases.

Phase 2 study of siRNA targeting angiotensinogen in patients with hypertension meets primary endpoint

News - Sep. 12, 2023

A greater than 15 mmHg reduction in 24-h ambulatory systolic BP was reported with the two highest single doses of the siRNA therapeutic zilebesiran, targeting hepatic angiotensinogen synthesis, at month 3 compared with placebo in the KARDIA 1 phase 2 trial.

Switching to DOAC associated with higher risk of bleeding in frail patients with AF

News - Sep. 12, 2023

ESC Congress 2023 The FRAIL-AF trial showed that frail older patients with AF who switched from VKA to a DOAC had a 69% higher risk of bleeding, compared with patients who continued using VKA. There was no difference between DOACs and VKA in stroke reduction in this patient population.

Ferric carboxymaltose reduces hospitalization risk in HF patients with iron deficiency

News - Sep. 12, 2023

ESC Congress 2023 In a large pooled analysis, intravenous ferric carboxymaltose reduced the risk of CV hospitalizations or CV death combined, but not mortality alone, in patients with HFrEF/HFmrEF and iron deficiency.

Mixture of Chinese herbs reduces the risk of CV death or HF hospitalization in patients with HFrEF

News - Sep. 12, 2023

ESC Congress 2023 The QUEST study demonstrates that qiliqiangxin, a mixture of 11 different herbs which is used in traditional Chinese medicine, reduces the risk of CV death or HF hospitalization in patients with HFrEF.

Phase 3 trial with ferric carboxymaltose in HFrEF does not meet hierarchical primary endpoint

News - Sep. 12, 2023

ESC Congress 2023 In HFrEF patients with iron deficiency, IV ferric carboxymaltose resulted in a modest albeit not statistically significant improvement in the hierarchical composite outcome of all-cause mortality, HF hospitalization, and change in exercise capacity.

GLP-1RA improves HF symptoms and physical function in patients with HFpEF and obesity

News - Sep. 12, 2023

ESC Congress 2023 STEP HFpEF showed that once-weekly semaglutide 2.4 mg improved HF-related symptoms, physical limitations and exercise function, and led to greater weight loss in patients with HFpEF and obesity, compared with placebo.

2023 Focused Update of ESC HF guidelines entails new recommendations in three sections

News - Sep. 12, 2023
Well before the next scheduled full ESC guideline on HF, new evidence of several RCTs that should change the management of patients with HF has become available. Therefore, the 2023 Focused Update was presented and published.

ESC Congress 2023 Well before the next scheduled full ESC guideline on HF, new evidence of several RCTs that should change the management of patients with HF has become available. Therefore, the 2023 Focused Update was presented and published.

Special attention to glucose-lowering medication with proven CV benefit and/or safety in 2023 ESC diabetes guidelines

News - Sep. 12, 2023
New recommendations in the 2023 ESC guidelines for the management of CVD in patient with diabetes include focus on glucose-lowering medication with proven CV benefit and/or safety and the new SCORE2-Diabetes risk score.

ESC Congress 2023 New recommendations in the 2023 ESC guidelines for the management of CVD in patient with diabetes include focus on glucose-lowering medication with proven CV benefit and/or safety and the new SCORE2-Diabetes risk score.

Improvement of early diagnosis of CVD in primary care patients with COPD or T2D

News - Sep. 4, 2023

ESC Congress 2023 In the RED-CVD trial, it was shown that a proactive diagnostic intervention strategy improves early diagnosis of CVD in primary care patients with COPD and/or T2D.

Agenda